• LABline
• 13 Jan, 2021

AvantGen announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development, according to a press release. AvantGen, based in San Diego, has identified a panel of high-affinity human monoclonal antibody clones that bind to two distinct epitopes on the receptor-binding domain of the SARS-CoV-2 spike protein.
Read more...